Inventiva S.A. (IVA.PA)
- Previous Close
3.1200 - Open
3.1000 - Bid --
- Ask --
- Day's Range
3.0100 - 3.1200 - 52 Week Range
2.0250 - 4.8400 - Volume
17,682 - Avg. Volume
66,839 - Market Cap (intraday)
157.39M - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
-- - EPS (TTM)
-2.4300 - Earnings Date Mar 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.30
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
www.inventivapharma.comRecent News: IVA.PA
Performance Overview: IVA.PA
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IVA.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IVA.PA
Valuation Measures
Market Cap
157.39M
Enterprise Value
167.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.84
Price/Book (mrq)
--
Enterprise Value/Revenue
9.61
Enterprise Value/EBITDA
-1.65
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.19%
Return on Equity (ttm)
-1,642.75%
Revenue (ttm)
23.16M
Net Income Avi to Common (ttm)
-110.43M
Diluted EPS (ttm)
-2.4300
Balance Sheet and Cash Flow
Total Cash (mrq)
27.34M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-42.89M
Research Analysis: IVA.PA
Company Insights: IVA.PA
IVA.PA does not have Company Insights